Linear Clinical Research Current Trials Menu

Meet our board of directors.

Linear board

Peter Leedman

Director of the Harry Perkins Institute of Medical Research, Head of the Perkins Laboratory for Cancer Medicine and Professor of Medicine at the University of Western Australia, Peter is our inaugural chairman and has been involved with Linear since its inception. While driving our growth from three staff in 2010 to ~100 in 2017, he has pursued his long-term interest in RNA biology, in particular microRNAs, and how this information can be harnessed for therapeutics in poor prognostic tumors (head and neck, liver and colon cancer). Peter has also co-founded miReven, a spin out company established to commercialise microRNA replacement therapy for cancer.

Todd Shand

After graduating from the University of Western Australia with first class honours in chemistry, Todd completed a Bachelor of Laws degree and then qualified as a patent attorney, winning a national prize for his performance in the qualifying examinations. Today, in addition to drafting and prosecuting patent applications, Todd’s practice heavily involves validity and infringement opinions, as well as contentious issues including oppositions and revocation actions in Australia and New Zealand. As such, he’s a mine of legal and regulatory information, with an exceptional understanding of the latest judicial interpretations of key legal principles in both jurisdictions.

James Williams

Co-founder and Investment Director at Yuuwa Capital LP, a venture capital firm based in Western Australia, James has a remarkable track record as an innovator and entrepreneur in the medical device and drug discovery and development arena, including nano drug reformulation. This experience includes playing pivotal leadership roles at ASX-listed Resonance Health, Argus Biomedical and iCeutica, where he played a critical part in securing regulatory approvals and driving commercial success. James is also a member of the Panel of Experts for the University of Western Australia’s Pathfinder Fund.

David Fuller

A respected biopharmaceutical executive and pharmaceutical physician, David has an impressive record of developing and commercialising new products, as well as establishing and nurturing businesses in complex international environments. His R&D experience encompasses pre-clinical, clinical development and medical and regulatory affairs, while he also has diverse therapeutic expertise spanning rheumatology, renal medicine, oncology, CNS / analgesia, dermatology, gastroenterology and infectious disease products. David’s leadership credentials are equally notable, having led five product approvals (US/EU) and multiple FDA and EMEA interactions for both orphan and major market products.

Key personnel

Andy Redfern

Andy is Consultant Medical Oncologist at Fiona Stanley Hospital, a translational cancer researcher with the University of Western Australia, and current clinical head of the Cancer Division at Harry Perkins Institute. He has active research projects in breast cancer, prostate cancer, melanoma and bowel cancer, with a focus on growth signalling and mechanisms of chemotherapy and hormone therapy resistance in cancer. In addition to conducting a variety of human trials of chemotherapies, hormone therapies and immune therapies, Andy also co-ordinates training for advanced medical oncology doctors in WA, and is the State Lead Clinical for breast cancer overseeing services.

Tony Spezzacatena

Finance Director and Company Secretary of the Harry Perkins Institute, Tony is responsible for the overall financial management of the Institute, including Linear Clinical Research. Previously, he held the position of Director of Finance at St John of God Hospital Murdoch and was a company director of a private day surgery hospital. He holds a Bachelor of Business degree in accounting and is a member of the Institute of Chartered Accountants of Australia.